These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2663834)

  • 1. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children.
    Anderson LT; Campbell M; Adams P; Small AM; Perry R; Shell J
    J Autism Dev Disord; 1989 Jun; 19(2):227-39. PubMed ID: 2663834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of haloperidol on learning and behavior in autistic children.
    Campbell M; Anderson LT; Small AM; Perry R; Green WH; Caplan R
    J Autism Dev Disord; 1982 Jun; 12(2):167-75. PubMed ID: 7174605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.
    Anderson LT; Campbell M; Grega DM; Perry R; Small AM; Green WH
    Am J Psychiatry; 1984 Oct; 141(10):1195-202. PubMed ID: 6385731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors related to haloperidol response and dyskinesias in autistic children.
    Locascio JJ; Malone RP; Small AM; Kafantaris V; Ernst M; Lynch NS; Overall JE; Campbell M
    Psychopharmacol Bull; 1991; 27(2):119-26. PubMed ID: 1924657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.
    Malone RP; Cater J; Sheikh RM; Choudhury MS; Delaney MA
    J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):887-94. PubMed ID: 11501687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic-related dyskinesias in autistic children: a prospective study.
    Perry R; Campbell M; Green WH; Small AM; Die Trill ML; Meiselas K; Golden RR; Deutsch SI
    Psychopharmacol Bull; 1985; 21(1):140-3. PubMed ID: 3885290
    [No Abstract]   [Full Text] [Related]  

  • 8. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study.
    Remington G; Sloman L; Konstantareas M; Parker K; Gow R
    J Clin Psychopharmacol; 2001 Aug; 21(4):440-4. PubMed ID: 11476129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
    Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.
    Ernst M; Devi L; Silva RR; Gonzalez NM; Small AM; Malone RP; Campbell M
    Psychopharmacol Bull; 1993; 29(2):221-7. PubMed ID: 8290669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study.
    Silver AA; Shytle RD; Philipp MK; Wilkinson BJ; McConville B; Sanberg PR
    J Clin Psychiatry; 2001 Sep; 62(9):707-14. PubMed ID: 11681767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fenfluramine in autistic children.
    Campbell M; Adams P; Small AM; Curren EL; Overall JE; Anderson LT; Lynch N; Perry R
    J Am Acad Child Adolesc Psychiatry; 1988 Jul; 27(4):434-9. PubMed ID: 3053609
    [No Abstract]   [Full Text] [Related]  

  • 13. Naltrexone in autistic children: behavioral symptoms and attentional learning.
    Campbell M; Anderson LT; Small AM; Adams P; Gonzalez NM; Ernst M
    J Am Acad Child Adolesc Psychiatry; 1993 Nov; 32(6):1283-91. PubMed ID: 8282676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should autistic children be treated with haloperidol?
    Ornitz EM
    Am J Psychiatry; 1985 Jul; 142(7):883-4. PubMed ID: 3893168
    [No Abstract]   [Full Text] [Related]  

  • 15. Haloperidol in schizophrenic children: early findings from a study in progress.
    Spencer EK; Kafantaris V; Padron-Gayol MV; Rosenberg CR; Campbell M
    Psychopharmacol Bull; 1992; 28(2):183-6. PubMed ID: 1513922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone in autistic children: a double-blind and placebo-controlled study.
    Campbell M; Anderson LT; Small AM; Locascio JJ; Lynch NS; Choroco MC
    Psychopharmacol Bull; 1990; 26(1):130-5. PubMed ID: 2196621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration.
    Perry R; Campbell M; Adams P; Lynch N; Spencer EK; Curren EL; Overall JE
    J Am Acad Child Adolesc Psychiatry; 1989 Jan; 28(1):87-92. PubMed ID: 2914841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of haloperidol in young autistic children: a within-subjects design using objective rating scales.
    Cohen IL; Campbell M; Posner D
    Psychopharmacol Bull; 1980 Jul; 16(3):63-5. PubMed ID: 7403407
    [No Abstract]   [Full Text] [Related]  

  • 19. Haloperidol withdrawal and weight changes in autistic children.
    Silva RR; Malone RP; Anderson LT; Shay J; Campbell M
    Psychopharmacol Bull; 1993; 29(2):287-91. PubMed ID: 8290679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of fenfluramine in autistic children: preliminary analysis of a double-blind study.
    Campbell M; Small AM; Palij M; Perry R; Polonsky BB; Lukashok D; Anderson LT
    Psychopharmacol Bull; 1987; 23(1):123-7. PubMed ID: 3602307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.